Role of immunotherapy in Bacillus Calmette-Guérin unresponsive: non-muscle invasive bladder cancer

Bacillus Calmette-Guérin (BCG) is recommended as the first-line treatment option for intermediate to high risk non-muscle invasive bladder cancer (NMIBC) by current clinical guidelines. However, despite the intravesical instillation of BCG, a significant proportion of patients with intermediate to h...

Descripción completa

Detalles Bibliográficos
Autores principales: Suh, Jungyo, Yoo, Sangjun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Review Article on Urothelial Carcinoma
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799067/
https://www.ncbi.nlm.nih.gov/pubmed/35117263
http://dx.doi.org/10.21037/tcr-20-758

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799067/
https://www.ncbi.nlm.nih.gov/pubmed/35117263
http://dx.doi.org/10.21037/tcr-20-758

Ejemplares similares